Trial · NCT00529659

A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(MK-0773-005)

NCT00529659, Phase 2, Completed, Merck Sharp & Dohme LLC; results first posted 2012-07-02

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(MK-0773-005). Trials, record NCT00529659. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00529659

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(MK-0773-005)
NCT number: NCT00529659
Status: Completed
Phases: Phase 2
Enrollment: 170 participants, actual
Lead sponsor: Merck Sharp & Dohme LLC
Conditions: Sarcopenia
Interventions: Comparator: MK-0773, Comparator: Placebo
First posted: 2007-09-14
Last updated: 2015-02-16
Results first posted: 2012-07-02

Source ClinicalTrials.gov

Registered outcomes6

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change From Baseline in Participant Lean Body Mass	Baseline, Month 6
Primary	Change From Baseline in Bilateral Leg Press (BLP) Measurement	Baseline, Month 6	BLP measurements were obtained with the participant sitting on the BLP exercise machine with flexed hips and knees. The participant held the handgrips with hips flexion and knees bent at a 90 degree angle and feet placed evenly on the footpad with heels placed approximately shoulder width apart. Participants were asked to slowly push the footpad forward, while keeping the knees slightly flexed, and bend back again slowly for one repetition. The BLP procedure measures the maximum amount of weight that the patient can push through his or her full range of motion one time.
Secondary	Change From Baseline in Participant Short Physical Performance Battery (SPPB)	Baseline, Month 6	The Short Physical Performance Battery (SPPB) is an objective assessment tool for evaluating lower extremity functioning in older persons. The SPPB consists of 3 types of physical maneuvers: balance test, speed gait test, and chair stand test. Results from each maneuvers test are scored on a scale of 0 to 4, with an increasing composite score indicating an improved function level. The total maximum score of SPPB is 12.
Secondary	Change From Baseline in Participant Gait Speed	Baseline, Month 6
Secondary	Change From Baseline in Stair Climbing Power	Baseline, Month 6	Stair-climbing power is an alternate measure of lower extremity muscle strength. Participants were asked to climb a standardized 4-step flight of stairs. The study coordinator timed how long it took the participant to walk up the stairs as quickly as possible. The test starts when the tester says "go" and ends when both of the patient's feet are flat on the platform area at the top of the staircase. Participants were permitted to use the railing, and/or an assistive device, if needed. Stair climbing power was calculated as = participant weight × gravity constant × height of stairs / time.
Secondary	Change From Baseline in Activity Measure for Post Acute Care (AM-PAC) Physical Movement Score	Baseline, Month 6	The Activity Measure for Post Acute Care (AM-PAC) measures function in three domains: basic mobility, daily activities, and applied cognitive function. AM-PAC scores in each functional domain have a mean of 50 with a standard deviation of 10 and scores are distributed along a continuum of function. The AM-PAC tracks outcomes as a participant progresses across an episode of care with higher scores indicating an improved level of functioning.

Source ClinicalTrials.gov

Outcomes6

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change From Baseline in Participant Lean Body Mass	Baseline, Month 6	The full analysis set (FAS) included all participants that received at least one dose of the study therapy and had a post-randomization measurement of lean body mass.	kg	MEAN
SECONDARY	Change From Baseline in Participant Short Physical Performance Battery (SPPB)	Baseline, Month 6	N = Number of participants with at least one non-missing measurement at the time point.	Score on a Scale	MEAN
PRIMARY	Change From Baseline in Bilateral Leg Press (BLP) Measurement	Baseline, Month 6	N = Number of participants with at least one non-missing measurement at the time point.	lbs	MEAN
SECONDARY	Change From Baseline in Participant Gait Speed	Baseline, Month 6	N = Number of participants with at least one non-missing measurement at the time point.	cm/sec	MEAN
SECONDARY	Change From Baseline in Stair Climbing Power	Baseline, Month 6	The FAS included all participants that received at least one dose of the study therapy and had a post-randomization stair climbing power measurement.	watts	MEAN
SECONDARY	Change From Baseline in Activity Measure for Post Acute Care (AM-PAC) Physical Movement Score	Baseline, Month 6	N = Number of patient with at least one non-missing measurement at the time point.	Score on a Scale	MEAN

Source ClinicalTrials.gov

Results by group14

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change From Baseline in Participant Lean Body Mass	MK-0773	1.26	Standard Deviation 1.09	kg
Change From Baseline in Participant Lean Body Mass	Placebo	0.29	Standard Deviation 1.29	kg
Change From Baseline in Participant Short Physical Performance Battery (SPPB)	MK-0773	0.92	Standard Deviation 1.63	Score on a Scale
Change From Baseline in Participant Short Physical Performance Battery (SPPB)	Placebo	0.88	Standard Deviation 1.60	Score on a Scale
Change From Baseline in Bilateral Leg Press (BLP) Measurement	MK-0773	17.42	Standard Deviation 26.04	lbs
Change From Baseline in Bilateral Leg Press (BLP) Measurement	Placebo	15.95	Standard Deviation 27.84	lbs
Change From Baseline in Participant Gait Speed	MK-0773	6.24	Standard Deviation 17.65	cm/sec
Change From Baseline in Participant Gait Speed	Placebo	8.91	Standard Deviation 15.05	cm/sec
Change From Baseline in Stair Climbing Power	MK-0773	19.68	Standard Deviation 23.85	watts
Change From Baseline in Stair Climbing Power	Placebo	14.98	Standard Deviation 20.71	watts

1 to 10 of 14Source ClinicalTrials.gov

See all 14 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	MK-0773	81
Overall Study	STARTED	Placebo	89
Overall Study	COMPLETED	MK-0773	70
Overall Study	COMPLETED	Placebo	66
Overall Study	NOT COMPLETED	MK-0773	11
Overall Study	NOT COMPLETED	Placebo	23

Source ClinicalTrials.gov

Adverse events322

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Normochromic normocytic anaemia	Blood and lymphatic system disorders	MK-0773	0	81	0
other	Normochromic normocytic anaemia	Blood and lymphatic system disorders	Placebo	1	89	1
other	Acute myocardial infarction	Cardiac disorders	MK-0773	0	81	0
other	Acute myocardial infarction	Cardiac disorders	Placebo	1	89	1
other	Aortic valve stenosis	Cardiac disorders	MK-0773	0	81	0
other	Aortic valve stenosis	Cardiac disorders	Placebo	1	89	1
other	Atrial fibrillation	Cardiac disorders	MK-0773	0	81	0
other	Atrial fibrillation	Cardiac disorders	Placebo	1	89	1
other	Cardiac failure	Cardiac disorders	MK-0773	0	81	0
other	Cardiac failure	Cardiac disorders	Placebo	1	89	1

1 to 10 of 322Source ClinicalTrials.gov

See all 322 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	MK-0773
Total, all-cause mortality	Placebo
Total, other adverse events	MK-0773	50	81
Total, other adverse events	Placebo	52	89
Total, serious adverse events	MK-0773	12	81
Total, serious adverse events	Placebo	9	89

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
23732550	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
MK-0773 vs Placebo: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00529659

GET https://conductscience.org/api/trials/v1/NCT00529659/events?page=2

API reference For AI assistants